article_metadata: Chunting Zhu Yi Zhao Fang Yu Weijia Huang Wenjun Wu Jingsong He Zhen Cai Donghua He
article_metadata: 10.3389/fimmu.2021.756583
article_metadata: Front Immunol
article_metadata: 2022 Jan 14;12:756583.
article_metadata: brentuximab vedotin classic hodgkin lymphoma immune related adverse event tislelizumab tumor flare reaction
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/35095839/
article_metadata: Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Brentuximab Vedotin / therapeutic use Hodgkin Disease / drug therapy
article_metadata: Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Brentuximab Vedotin / therapeutic use Hodgkin Disease / drug therapy Case Reports Research Support, Non-U.S. Gov't Adult Female Humans Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological tislelizumab Brentuximab Vedotin
article_metadata: PMC8795608
article_metadata: 35095839
article_metadata: Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
article_metadata: 2022